Web Analytics

3 Latest Announced Rounds

  • $38,000,000
    Series C

    1 Investors

    Financial Services
    Aug 5th, 2025
  • $8,000,000
    Unknown
    Pharmaceutical Manufacturing
    Aug 5th, 2025
  • $2,600,000
    Pre-Seed

    2 Investors

    Software Development
    Aug 5th, 2025
$1,254.05M Raised in 56 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Volastra Therapeutics

start up
United States - New York, New York
  • 08/03/2023
  • Series A
  • $60,000,000

Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is rapidly developing and implementing new methods to exploit this vulnerability. Leveraging its proprietary CINtech platform, the company is advancing a novel synthetic lethal and immune activating pipeline.


Related People

Charles Hugh-JonesFounder

Charles Hugh-Jones United States - New York City Metropolitan Area

N/A